-
Je něco špatně v tomto záznamu ?
Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial
CS. Tam, JR. Brown, BS. Kahl, P. Ghia, K. Giannopoulos, W. Jurczak, M. Šimkovič, M. Shadman, A. Österborg, L. Laurenti, P. Walker, S. Opat, H. Chan, H. Ciepluch, R. Greil, M. Tani, M. Trněný, DM. Brander, IW. Flinn, S. Grosicki, E. Verner, A....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie, práce podpořená grantem
NLK
ProQuest Central
od 2000-09-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
Health & Medicine (ProQuest)
od 2000-09-01 do Před 2 měsíci
Public Health Database (ProQuest)
od 2000-09-01 do Před 2 měsíci
- MeSH
- bendamustin hydrochlorid MeSH
- chronická lymfatická leukemie * farmakoterapie patologie MeSH
- COVID-19 * MeSH
- lidé MeSH
- piperidiny MeSH
- protokoly antitumorózní kombinované chemoterapie škodlivé účinky MeSH
- pyrazoly MeSH
- pyrimidiny MeSH
- rituximab MeSH
- sekvoj * MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky, fáze III MeSH
- práce podpořená grantem MeSH
- randomizované kontrolované studie MeSH
BACKGROUND: Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL. METHODS: We conducted an open-label, multicentre, phase 3 study at 153 academic or community hospitals in 14 countries and regions. Eligible patients had untreated CLL or SLL requiring treatment as per International Workshop on CLL criteria; were aged 65 years or older, or 18 years or older and had comorbidities; and had an Eastern Cooperative Oncology Group performance status score of 0-2. A central interactive web response system randomly assigned patients without del(17)(p13·1) to zanubrutinib (group A) or bendamustine-rituximab (group B) by sequential block method (permutated blocks with a random block size of four). Patients with del(17)(p13·1) were enrolled in group C and received zanubrutinib. Zanubrutinib was administered orally at 160 mg twice per day (28-day cycles); bendamustine at 90 mg/m2 of body surface area on days 1 and 2 for six cycles plus rituximab at 375 mg/m2 of body surface area the day before or on day 1 of cycle 1, and 500 mg/m2 of body surface area on day 1 of cycles 2-6, were administered intravenously. The primary endpoint was progression-free survival per independent review committee in the intention-to-treat population in groups A and B, with minimum two-sided α of 0·05 for superiority. Safety was analysed in all patients who received at least one dose of study treatment. The study is registered with ClinicalTrials.gov, NCT03336333, and is closed to recruitment. FINDINGS: Between Oct 31, 2017, and July 22, 2019, 590 patients were enrolled; patients without del(17)(p13·1) were randomly assigned to zanubrutinib (group A; n=241) or bendamustine-rituximab (group B; n=238). At median follow-up of 26·2 months (IQR 23·7-29·6), median progression-free survival per independent review committee was not reached in either group (group A 95% CI not estimable [NE] to NE; group B 28·1 months to NE). Progression-free survival was significantly improved in group A versus group B (HR 0·42 [95% CI 0·28 to 0·63]; two-sided p<0·0001). The most common grade 3 or worse adverse event was neutropenia (27 [11%] of 240 patients in group A, 116 [51%] of 227 in group B, and 17 [15%] of 111 patients in group C). Serious adverse events occurred in 88 (37%) of 240 patients in group A, 113 (50%) of 227 patients in group B, and 45 (41%) of 111 patients in group C. Adverse events leading to death occurred in 11 (5%) of 240 patients in group A, 12 (5%) of 227 patients in group B, and three (3%) of 111 patients in group C, most commonly due to COVID-19 (four [2%] of 240 patients in group A), diarrhoea, and aspiration pneumonia (two each [1%] of 227 patients in group B). INTERPRETATION: Zanubrutinib significantly improved progression-free survival versus bendamustine-rituximab, with an acceptable safety profile consistent with previous studies. These data support zanubrutinib as a potential new treatment option for untreated CLL and SLL. FUNDING: BeiGene.
4th Department of Internal Medicine Haematology University Hospital Hradec Kralove Czech Republic
ASST Grande Ospedale Metropolitano Niguarda Milan Italy
Cancer Cluster Salzburg Salzburg Austria
Concord Repatriation General Hospital Concord NSW Australia
Copernicus Regional Oncology Center Gdansk Poland
Dana Farber Cancer Institute Boston MA USA
Department of Hematology Karolinska University Hospital Stockholm Sweden
Department of Medicine University of Washington Seattle WA USA
Department of Oncology Pathology Karolinska Institutet Stockholm Sweden
Experimental Hematooncology Department Medical University of Lublin Lublin Poland
Faculty of Medicine Charles University Prague Czech Republic
Fondazione Policlinico Universitario A Gemelli UCSC Rome Italy
Fred Hutchinson Cancer Research Center Seattle WA USA
Hematologic Malignancies and Cellular Therapy Duke University School of Medicine Durham NC USA
Hematology Department St John's Cancer Centre Lublin Poland
Hematology Unit Santa Maria delle Croci Hospital Ravenna Italy
Maria Sklodowska Curie National Research Institute of Oncology Krakow Poland
Medical University of Lodz Lodz Poland
Monash Health Clayton VIC Australia
Monash University Clayton VIC Australia
North Shore Hospital Auckland New Zealand
Peninsula Private Hospital Frankston VIC Australia
Peter MacCallum Cancer Centre Melbourne VIC Australia
Royal Melbourne Hospital Parkville VIC Australia
Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials Salzburg Austria
Sarah Cannon Research Institute Tennessee Oncology Nashville TN USA
St James's University Hospital Leeds UK
St Vincent's Hospital Melbourne Fitzroy VIC Australia
Università Vita Salute San Raffaele and IRCCS Ospedale San Raffaele Milano Italy
University of Melbourne Parkville VIC Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22025075
- 003
- CZ-PrNML
- 005
- 20221031100227.0
- 007
- ta
- 008
- 221017s2022 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/S1470-2045(22)00293-5 $2 doi
- 035 __
- $a (PubMed)35810754
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Tam, Constantine S $u Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC, Australia; St Vincent's Hospital Melbourne, Fitzroy, VIC, Australia; Royal Melbourne Hospital, Parkville, VIC, Australia. Electronic address: constantine.tam@alfred.org.au
- 245 10
- $a Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial / $c CS. Tam, JR. Brown, BS. Kahl, P. Ghia, K. Giannopoulos, W. Jurczak, M. Šimkovič, M. Shadman, A. Österborg, L. Laurenti, P. Walker, S. Opat, H. Chan, H. Ciepluch, R. Greil, M. Tani, M. Trněný, DM. Brander, IW. Flinn, S. Grosicki, E. Verner, A. Tedeschi, J. Li, T. Tian, L. Zhou, C. Marimpietri, JC. Paik, A. Cohen, J. Huang, T. Robak, P. Hillmen
- 520 9_
- $a BACKGROUND: Zanubrutinib is a next-generation, selective Bruton tyrosine kinase inhibitor with efficacy in relapsed chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). We compared zanubrutinib with bendamustine-rituximab to determine its effectiveness as frontline therapy in patients with CLL or SLL. METHODS: We conducted an open-label, multicentre, phase 3 study at 153 academic or community hospitals in 14 countries and regions. Eligible patients had untreated CLL or SLL requiring treatment as per International Workshop on CLL criteria; were aged 65 years or older, or 18 years or older and had comorbidities; and had an Eastern Cooperative Oncology Group performance status score of 0-2. A central interactive web response system randomly assigned patients without del(17)(p13·1) to zanubrutinib (group A) or bendamustine-rituximab (group B) by sequential block method (permutated blocks with a random block size of four). Patients with del(17)(p13·1) were enrolled in group C and received zanubrutinib. Zanubrutinib was administered orally at 160 mg twice per day (28-day cycles); bendamustine at 90 mg/m2 of body surface area on days 1 and 2 for six cycles plus rituximab at 375 mg/m2 of body surface area the day before or on day 1 of cycle 1, and 500 mg/m2 of body surface area on day 1 of cycles 2-6, were administered intravenously. The primary endpoint was progression-free survival per independent review committee in the intention-to-treat population in groups A and B, with minimum two-sided α of 0·05 for superiority. Safety was analysed in all patients who received at least one dose of study treatment. The study is registered with ClinicalTrials.gov, NCT03336333, and is closed to recruitment. FINDINGS: Between Oct 31, 2017, and July 22, 2019, 590 patients were enrolled; patients without del(17)(p13·1) were randomly assigned to zanubrutinib (group A; n=241) or bendamustine-rituximab (group B; n=238). At median follow-up of 26·2 months (IQR 23·7-29·6), median progression-free survival per independent review committee was not reached in either group (group A 95% CI not estimable [NE] to NE; group B 28·1 months to NE). Progression-free survival was significantly improved in group A versus group B (HR 0·42 [95% CI 0·28 to 0·63]; two-sided p<0·0001). The most common grade 3 or worse adverse event was neutropenia (27 [11%] of 240 patients in group A, 116 [51%] of 227 in group B, and 17 [15%] of 111 patients in group C). Serious adverse events occurred in 88 (37%) of 240 patients in group A, 113 (50%) of 227 patients in group B, and 45 (41%) of 111 patients in group C. Adverse events leading to death occurred in 11 (5%) of 240 patients in group A, 12 (5%) of 227 patients in group B, and three (3%) of 111 patients in group C, most commonly due to COVID-19 (four [2%] of 240 patients in group A), diarrhoea, and aspiration pneumonia (two each [1%] of 227 patients in group B). INTERPRETATION: Zanubrutinib significantly improved progression-free survival versus bendamustine-rituximab, with an acceptable safety profile consistent with previous studies. These data support zanubrutinib as a potential new treatment option for untreated CLL and SLL. FUNDING: BeiGene.
- 650 _2
- $a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
- 650 _2
- $a bendamustin hydrochlorid $7 D000069461
- 650 12
- $a COVID-19 $7 D000086382
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a chronická lymfatická leukemie $x farmakoterapie $x patologie $7 D015451
- 650 _2
- $a piperidiny $7 D010880
- 650 _2
- $a pyrazoly $7 D011720
- 650 _2
- $a pyrimidiny $7 D011743
- 650 _2
- $a rituximab $7 D000069283
- 650 12
- $a sekvoj $7 D032487
- 655 _2
- $a klinické zkoušky, fáze III $7 D017428
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Brown, Jennifer R $u Dana-Farber Cancer Institute, Boston, MA, USA
- 700 1_
- $a Kahl, Brad S $u Washington University School of Medicine, St Louis, MO, USA
- 700 1_
- $a Ghia, Paolo $u Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy
- 700 1_
- $a Giannopoulos, Krzysztof $u Experimental Hematooncology Department, Medical University of Lublin, Lublin, Poland; Hematology Department, St John's Cancer Centre, Lublin, Poland
- 700 1_
- $a Jurczak, Wojciech $u Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland
- 700 1_
- $a Šimkovič, Martin $u Fourth Department of Internal Medicine-Haematology, University Hospital, Hradec Kralove, Czech Republic; Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Shadman, Mazyar $u Fred Hutchinson Cancer Research Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA
- 700 1_
- $a Österborg, Anders $u Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; Department of Hematology, Karolinska University Hospital, Stockholm, Sweden
- 700 1_
- $a Laurenti, Luca $u Fondazione Policlinico Universitario A Gemelli UCSC, Rome, Italy
- 700 1_
- $a Walker, Patricia $u Peninsula Private Hospital, Frankston, VIC, Australia
- 700 1_
- $a Opat, Stephen $u Monash Health, Clayton, VIC, Australia; Monash University, Clayton, VIC, Australia
- 700 1_
- $a Chan, Henry $u North Shore Hospital, Auckland, New Zealand
- 700 1_
- $a Ciepluch, Hanna $u Copernicus Regional Oncology Center, Gdansk, Poland
- 700 1_
- $a Greil, Richard $u Third Medical Department with Hematology, Medical Oncology, Rheumatology and Infectiology, Paracelsus Medical University, Salzburg, Austria; Salzburg Cancer Research Institute Center for Clinical Cancer and Immunology Trials, Salzburg, Austria; Cancer Cluster Salzburg, Salzburg, Austria
- 700 1_
- $a Tani, Monica $u Hematology Unit, Santa Maria delle Croci Hospital, Ravenna, Italy
- 700 1_
- $a Trněný, Marek $u First Department of Medicine, First Faculty of Medicine, Charles University, General Hospital, Prague, Czech Republic
- 700 1_
- $a Brander, Danielle M $u Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA
- 700 1_
- $a Flinn, Ian W $u Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA
- 700 1_
- $a Grosicki, Sebastian $u Department of Hematology and Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland
- 700 1_
- $a Verner, Emma $u Concord Repatriation General Hospital, Concord, NSW, Australia; University of Sydney, Sydney, NSW, Australia
- 700 1_
- $a Tedeschi, Alessandra $u ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
- 700 1_
- $a Li, Jianyong $u Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
- 700 1_
- $a Tian, Tian $u BeiGene USA, San Mateo, CA, USA
- 700 1_
- $a Zhou, Lei $u BeiGene, Beijing, China
- 700 1_
- $a Marimpietri, Carol $u BeiGene USA, San Mateo, CA, USA
- 700 1_
- $a Paik, Jason C $u BeiGene USA, San Mateo, CA, USA
- 700 1_
- $a Cohen, Aileen $u BeiGene USA, San Mateo, CA, USA
- 700 1_
- $a Huang, Jane $u BeiGene USA, San Mateo, CA, USA
- 700 1_
- $a Robak, Tadeusz $u Medical University of Lodz, Lodz, Poland
- 700 1_
- $a Hillmen, Peter $u St James's University Hospital, Leeds, UK
- 773 0_
- $w MED00011558 $t Lancet oncology $x 1474-5488 $g Roč. 23, č. 8 (2022), s. 1031-1043
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35810754 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20221017 $b ABA008
- 991 __
- $a 20221031100225 $b ABA008
- 999 __
- $a ok $b bmc $g 1854671 $s 1176365
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 23 $c 8 $d 1031-1043 $e 20220707 $i 1474-5488 $m Lancet oncology $n Lancet Oncol. $x MED00011558
- LZP __
- $a Pubmed-20221017
